NovaBiotics Ltd was founded in Aberdeen by Dr. Deborah O’Neil in 2004. The board of directors provides a wealth of commercial expertise and specific knowledge of the biotechnology and pharmaceutical sectors.

The dynamic science team now in place (comprising immunology, microbiology and peptide antimicrobial expertise) provides a wealth of technological know-how that when combined with the substantial business experience of executive management and the board, creates the optimal balance of synergistic skill sets to drive the business forward and build on the success achieved to date.

Financing to Date

NovaBiotics has raised £5M in private equity funding and support.

The Business Model

NovaBiotics will complete preclinical and early clinical R&D (phase II) for each indication and then aims to form strategic alliance and out-licensing agreements with pharmaceutical partners for late stage clinical and regulatory testing, manufacture and marketing.  Revenue from such alliances will be re-invested into pipeline development and growth of the technology base which in turn, will pave the way for additional revenue generating alliances. 

This step-wise market penetration strategy will generate a steady income stream to facilitate expansion of the company in such as way as to negate the requirement for further equity investment, provide investors with clear exits and add significant value to the company.